Seeking Alpha
View as an RSS Feed

Stock Reversals  

View Stock Reversals' Comments BY TICKER:
Latest  |  Highest rated
  • A Catalyst For WMI Holdings To Finally Begin Utilizing Their NOLs [View article]
    We come up with a fair value of about $2.83 per share as a shell. Basically this is trading at a bit of a discount, almost like a closed end fund below NAV.

    Loosely we assume 530 million fully diluted shares
    We take 6 Billion of NOL's and discount at 6% over 10 years use to get 3.3 Billion
    We take 28% of that for tax amount or about 900 million

    We add the cash of 600 million plus 900 million and come up with about 1.5 Billion

    Divided by 530mm fully diluted we are around $2.83 per share

    Its quick and dirty, but relatively accurate plus minus 5-8% or so on either side.

    SO you can buy the stock at 2.50 here on this pullback and have about a 10-13% discount to fair value before anything gets started.

    Just our 2...
    Apr 29, 2015. 12:31 PM | 1 Like Like |Link to Comment
  • Concert Pharmaceuticals: The Deuterated Drug Platform, A Profitable Way To Reinvent The Wheel [View article]
    one of our favorites
    Apr 18, 2015. 10:45 AM | 3 Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    As in full FDA approval, they could give conditional use approval with safety studies ongoing
    Apr 3, 2015. 05:34 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    FDA approval, we dont mean phase2b data hitting... we mean FDA approval, that could be another 12-18 months etc...
    Apr 2, 2015. 09:43 PM | Likes Like |Link to Comment
  • Celladon: The Next Breakthrough In Cardiovascular Gene Therapy? [View article]
    NO, our plan all along was load up at 16-18, then sell at 21-23 if it got there 1/2 of the position before MYDICAR. Then ROTH Came out with a $70 target and all heck broke loose, we sold at 26-27 at our service in that March 12-13 window 1/2. We held 1/2 and that is our plan holding that 1/2 into MYDICAR data...
    Mar 31, 2015. 04:09 PM | 2 Likes Like |Link to Comment
  • Celladon: The Next Breakthrough In Cardiovascular Gene Therapy? [View article]
    yep...we wrote this up at 17 in January. Sold half at 26...holding rest
    Mar 31, 2015. 08:49 AM | 3 Likes Like |Link to Comment
  • Trevena's Q4 2014 Results Conference Call - What We Learned [View article]
    We continue to like this one long term, our report came out March 12th at 5.75... nice pullback this week, it got pretty overheated with retail chasers... slow and steady wins the race...
    Mar 28, 2015. 12:30 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    Retail traders set stop losses and then the computers run them often... at our SRP service we advised our members to sell 1/2 their CLDN at 26-27 about 2 weeks ago during the huge run up after Roth put that fat target on the shares. We had been buying from 16-18.... so we are long 1/2 now into MYDICAR data... this is really the best way to play these data related stocks. That said, we feel good about the upside here... but we never bet the farm on one stock...
    Mar 27, 2015. 04:30 PM | 1 Like Like |Link to Comment
  • T2 Biosystems: Impressive Opportunity With Sepsis Diagnosis [View article]
    already long at SRP I wrote a full report 2 weeks ago.
    Mar 26, 2015. 10:11 AM | 2 Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    80... at least
    Mar 24, 2015. 10:41 PM | 2 Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    No worries we as you know are long from much lower levels and our target was $80 upon approval, $35 plus if MYDICAR data hits...
    Mar 24, 2015. 03:23 PM | Likes Like |Link to Comment
  • Trevena's Q4 2014 Results Conference Call - What We Learned [View article]
    Here is our work from March 12th
    http://seekingalpha.co...

    We sent it to our SRP members and also SR members as well same morning, but posted it on our insta blog since we made it available to the free members and the public.
    Mar 23, 2015. 07:34 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    Analysts are using 36,000 in their models not 75,000. Also , its a single dose and penetration would take quite some time. Nonetheless, we remain bullish
    Mar 23, 2015. 07:28 PM | Likes Like |Link to Comment
  • Trevena's Q4 2014 Results Conference Call - What We Learned [View article]
    We wrote a full report on this company several days before your Seeking Alpha piece hit and we are long from about 5 75
    Mar 23, 2015. 03:31 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    We sold 1/2 our position at our SRP service and held 1/2, so that is how we are playing it. We took 50% profits and will ride into MYDICAR.
    Mar 22, 2015. 09:02 PM | Likes Like |Link to Comment
COMMENTS STATS
297 Comments
263 Likes